Antwerp-based HealthTech startup Koios Care has closed a €1 million funding spherical to speed up its efforts in reworking the monitoring and remedy of Parkinson’s Illness with its AI-powered platform that passively collects information from smartphones and smartwatches.
The spherical was led by Greek early-stage DeepTech investor Evercurious VC, with participation from Astylab Ventures, the imec.istart fund, and several other angel traders, together with these coordinated by HeBAN. The brand new funding will assist Koios Care increase its digital well being instrument ‘Parkiwatch’ throughout European clinics, help regulatory clearance efforts, and construct stronger partnerships with pharma firms and analysis establishments.
“There’s a major hole between what folks with Parkinson’s really want and what they at present obtain. It’s not nearly managing signs, it’s about meaningfully bettering their total High quality of Life. That’s the hole Koios Care is right here to shut,” mentioned Dr Konstantinos Kyritsis, Co-founder and CEO “One affected person utilizing the expertise to obviously talk with their neurologist instructed us, ‘Typically, on my present medicine scheme, it looks like I’ve no Parkinson’s.’ That’s not simply encouraging, it’s a robust glimpse of what’s doable. It’s the type of transformation we’re relentlessly working to ship for everybody residing with this illness.”
Based by Dr Konstantinos Kyritsis and Dr Dimitris Iakovakis, Koios Care bridges the hole between sufferers’ every day lives and scientific care. The group’s answer permits care groups to make earlier and extra personalised choices, based mostly on goal, real-life proof – moderately than occasional clinic visits or self-reports.
Koios is creating an AI-powered platform that passively collects information from smartphones and smartwatches to offer clinicians and researchers with real-world, clinically significant insights into neurological issues.
Koios Care is responding to it referrs to as a “silent pandemic” – the fast world rise of Parkinson’s Illness, which reportedly now impacts greater than ten million folks. By leveraging information from on a regular basis gadgets, the corporate goals to personalise and enhance care whereas streamlining scientific workflows and supporting simpler drug growth.
Koios Care’s mannequin helps each sufferers and the broader healthcare ecosystem. For clinicians and sufferers, it gives a digital instrument to information remedy choices and monitor outcomes; for pharma and MedTech companies, it affords an R&D platform that may generate real-world information and determine significant endpoints for scientific trials.
“For too lengthy, sufferers, clinicians and researchers have lacked steady, goal information to really personalise Parkinson’s care and perceive the real-life affect of the illness and its therapies,” mentioned Dr Iakovakis, Co-founder and CTO of Koios Care. “This funding displays the pressing want for a brand new customary in care. With our answer, we empower sufferers to raised perceive their situation, equip medical groups with unprecedented insights, and supply pharmaceutical firms with a robust instrument to speed up the event of simpler therapies.”
Thus far, Koios Care has studied 130 sufferers in a multi-centre EU trial and is working with hospital pilot websites and business companions throughout Europe. The platform aligns with present regulatory steering on digital well being instruments and is designed to enhance therapeutic decision-making and trial success charges by reflecting real-world affected person outcomes.
Alex Vamvakas, companion at Evercurious VC, commented, “Koios Care’s modern strategy to passively monitoring High quality of Life with on a regular basis gadgets is a game-changer for neurodegenerative issues. We’re impressed by the group’s scientific rigor, the scientific validation and the imaginative and prescient to reshape long-term neurodegenerative circumstances’ care and allow the shift towards personalised, data-driven illness administration at scale.
“With roots in Greece and Belgium, and collaborators throughout Europe, Koios Care exemplifies the type of area bridging, self-discipline spanning, impact-driven innovation {that a} extra linked European DeepTech ecosystem can unlock. It displays a imaginative and prescient of Europe the place scientific excellence and entrepreneurial ambition transcend borders to resolve urgent world challenges.”
Wanting ahead, Koios Care plans to develop drug-device mixture merchandise and increase its attain to different mind and behaviour-related circumstances, together with Gentle Cognitive Impairment, Alzheimer’s, narcolepsy, and consuming issues. The startup is focusing on areas the place real-time, real-world information stays a crucial lacking hyperlink in care and analysis.
